| Document Date: 2014-06-25 05:00:42
Open Document File Size: 367,01 KBShare Result on Facebook
City West Trenton / Lake Zurich / New York / Rahway / / Company Novartis Pharmaceuticals Corporation / FRESENIUS KABI USA LLC / APP Pharmaceuticals Inc. / Sandoz Inc. / Pfizer Inc. / MCA / Merck / Preston K. Ratliff II PAUL HASTINGS LLP / Fenwal Inc. / Defendant Fresenius Kabi USA LLC / Glaxo Group Ltd. / Merck Sharp & Dohme Corp. / Billups MERCK SHARP & DOHME CORP. / Plaintiff Merck Sharp & Dohme Corp. / Lizza William C. Baton SAUL EWING LLP / / Country United States / / / Event FDA Phase / M&A / Company Expansion / Legal Issues / / Facility Whitehouse Station / Charles M. Lizza William C. Baton SAUL EWING LLP One Riverfront Plaza / / IndustryTerm dimeglumine product / injectable pharmaceutical products / “pharmaceuticals and medical devices / generic pharmaceutical versions / chemical name / generic pharmaceutical drugs / fosaprepitant dimeglumine product / / MedicalCondition nausea / acute and delayed nausea / moderately emetogenic cancer / injury / vomiting / highly emetogenic cancer / / MedicalTreatment chemotherapy / / Organization United States Food and Drug Administration / United States Patent and Trademark Office / UN Court / / Person Bruce M. Wexler Joseph / William Krovatin Gerard Devlin Richard / / / Position COUNSEL / Jersey Secretary of State / / Product cisplatin / EMEND / Acetylcysteine / Federal Food / Fresenius / NK-1 / EQ / EMEND® IV / / ProvinceOrState New Jersey / Illinois / New York / Delaware / New / / Technology html / chemotherapy / / URL http /
SocialTag |
Case 3:14-cv[removed]PGS-LHG Document 1 Filed[removed]Page 1 of 31 PageID: 1 Charles M. Lizza William C. Baton SAUL EWING LLP One Riverfront Plaza, Suite 1520